CDT EQUITY INC (CDT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.04-16.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CDT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of —
CDT — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-11-04
Material Modification to Rights of Security Holders. To the extent required by
Why it matters: The evaluation alone does not bring licensing or sales. A signed deal would show that the assets cleared a key step.
Supportive ifCDT and Manoira sign a license or sales deal for products that use AZD1656 or AZD5904.
Worry ifManoira finishes its tests without a license deal, or says the assets did not help its products.
Why it matters: Manoira plans its first product range for Q1 2027. A launch creates a chance to test CDT’s assets in animal health.
Supportive ifManoira confirms a Q1 2027 launch, and reports that AZD1656 or AZD5904 improves a product’s safety, use, or effect.
Worry ifManoira delays the launch beyond Q1 2027, or reports that neither CDT asset helps its planned products.
Why it matters: The supplied data show a $3.0 million operating loss in 2026-Q2 and no revenue figure. The next report can show whether that changed.
Watch forThe Nov. 12 report shows a smaller operating loss than $3.0 million, or reports revenue from a license or product deal.
Also watch forThe Nov. 12 report shows an operating loss of $3.0 million or more, with no reported revenue.
Why it matters: CDT has secured notes with weekly payments and possible share conversion. New shares or missed payments could add strain.
Worry ifA filing shows a missed weekly payment, default, or new shares issued to repay or convert the notes.
Less concerning ifCDT makes its disclosed weekly payments on time. No new default or added conversion shares are reported.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$783 on $10,000 · ±7.8% | How much price usually moves either way. |
| Bad day | $2,680 loss on $10,000 · 26.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $10,000 loss on $10,000 · 100.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.